Want to see ISPC full AI Analyst Report?
ISPC Stock Chart & Stats
$0.31
-$0.03(-1.03%)
At close: 4:00 PM EST
$0.31
-$0.03(-1.03%)
Day’s Range― - ―
52-Week Range$2.06 - $127.20
Previous CloseN/A
Volume25.67K
Average Volume (3M)8.88M
Market Cap
$3.36M
Enterprise Value$5.03
Total Cash (Recent Filing)$2.82M
Total Debt (Recent Filing)$254.99K
Price to Earnings (P/E)―
Beta1.37
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding1,522,359
10 Day Avg. Volume698,577
30 Day Avg. Volume8,882,166
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.39
Price to Sales (P/S)0.62
P/FCF Ratio-0.28
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Platform Upgrade (Milestone 3)The Milestone 3 digital transformation completion strengthens the marketplace infrastructure and partner integrations. A more robust platform and wider geographic rollout can sustainably improve matching efficiency, expand supplier/buyer reach, and lower unit fulfillment costs, supporting order volume and margin recovery over months.
Low Financial LeverageVery low debt affords structural flexibility: limited interest burden and greater capacity to absorb operating volatility or pursue incremental financing without immediate solvency pressure. That balance-sheet posture improves survival odds and strategic optionality while addressing ongoing cash needs over the medium term.
Two-sided Marketplace ModelThe core marketplace connects buyers and specimen suppliers, creating network effects and recurring fee-based revenue as adoption grows. Structural industry demand for biospecimens in diagnostics and drug development supports durable addressable market and potential scale benefits if platform activation and supplier breadth continue to expand.
Bears Say
Severe Revenue Decline & LossesSharp top-line contraction and outsized operating losses materially reduce scale economies and erode capital. Persistent negative margins undermine profitability prospects and force reliance on external financing to sustain operations, weakening long-term margin sustainability and strategic investment capacity if revenue recovery stalls.
Material Cash Burn And Negative FCFConsistent operating cash outflows and negative free cash flow indicate the business is not self-funding growth or working capital. This structural cash burn shortens runway, forces recurring capital raises, constrains reinvestment in the marketplace and increases execution risk over the next several months without durable revenue improvement or financing access.
Listing Risk & Dilution OverhangFailure to meet Nasdaq equity standards creates a material listing risk that could limit access to public capital if unresolved. Coupled with approved incentive plans and recent dilutive financings/reverse split, this raises structural dilution and governance overhangs that can impair investor confidence and constrain fundraising options over the medium term.
iSpecimen News
ISPC FAQ
What was iSpecimen’s price range in the past 12 months?
iSpecimen lowest stock price was $2.06 and its highest was $127.20 in the past 12 months.
What is iSpecimen’s market cap?
iSpecimen’s market cap is $3.36M.
When is iSpecimen’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were iSpecimen’s earnings last quarter?
Currently, no data Available
Is iSpecimen overvalued?
According to Wall Street analysts iSpecimen’s price is currently Overvalued.
Does iSpecimen pay dividends?
iSpecimen does not currently pay dividends.
What is iSpecimen’s EPS estimate?
iSpecimen’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does iSpecimen have?
iSpecimen has 1,522,359 shares outstanding.
What happened to iSpecimen’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of iSpecimen?
Currently, no hedge funds are holding shares in ISPC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
iSpecimen
iSpecimen Inc. operates a sophisticated technological platform that effectively bridges the gap between life science researchers and crucial human biological materials. Its proprietary cloud-based system empowers scientists to efficiently locate and access a vast array of biospecimens—such as biofluids, tissues, and living cells—as well as connect with potential study subjects, all sourced from a global network of healthcare providers, including hospitals, laboratories, biobanks, and blood centers. The company develops and manages iSpecimen Marketplace, an innovative online hub that strategically links medical researchers requiring access to subjects, samples, and pertinent data with organizations that hold these invaluable resources. iSpecimen's clientele primarily includes biopharmaceutical firms, in vitro diagnostics companies, and governmental and academic research institutions. The company, established in 2009, is headquartered in Lexington, Massachusetts.
Technical Analysis
―
Intelligent Bio Solutions
―
BioNexus Gene Lab Corp
―
―
bioAffinity Technologies, Inc.
―
Ownership Overview
―
Insiders
4.17% Mutual Funds
― Other Institutional Investors
95.82% Public Companies and
Individual Investors